News Medical Life Sciences
Genomic Press
Sep 4 2024

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the persistent symptoms that plague many survivors of viral infections. The study, published on 30 August 2024 in Brain Medicine (ISSN: 2997-2639, Genomic Press, New York), outlines a multimodal treatment strategy that could offer hope to millions suffering from post-acute infectious syndromes (PAIS), including the condition commonly known as Long COVID.

BY Kenny Cheng August 19, 2024

Yale Medicine

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia

Hiten Naik et al. Online issue publication May 13, 2024

Griffith University researchers to trial naltrexone on long COVID patients

By Janelle Miles and Emma Pollard

Posted Mon 6 May 2024

https://www.abc.net.au/news/2024-05-07/qld-griffith-university-trial-naltrexone-long-covid/103800050

Jayden Donald went from a fit and healthy teenager who rode his horses almost every day, to being so sick he could hardly sit up after his second bout of COVID-19.

Exciting breakthrough offers hope for Long COVID patients

Published May 7, 2024
Author Emma O'Connor - Griffith University

https://news.griffith.edu.au/2024/05/07/exciting-breakthrough-offers-hope-for-long-covid-patients/

Opioid Addiction Medication Could Bring Relief to Long COVID Patients

Naltrexone offers hope for alleviating various long COVID symptoms, including brain fog and muscle fatigue.

Published: May 9, 2024  Blake Forman

Technology Networks, Immunology & Microbiology